Positive DSMB Review in Phase 1/2 Kidney Transplant Trial
Filed with ASX · · 2 pages · English
• Independent DSMB review of trial Cohort 1 completed with no safety concerns identified and clearance to proceed to Cohort 2. • Demonstrates initial safety and tolerability of Cynata’s Cymerus™ MSC therapy (CYP-001) in kidney transplant recipients. • This Phase 1/2 study is managed and funded by Leiden University Medical Centre (LUMC), a global leader in kidney transplantation. • CYP-001 has pote
Cynata Therapeutics Limited on 6ix
Story so far
Earlier from Cynata Therapeutics
- Final Patient Visit Complete in Phase 3 Osteoarthritis Trial
- Cynata Receives $1.7m R&D Tax Incentive Refund
- September 2025 Quarterly Activity Report and Appendix 4C
- Appendix 4E & Annual Report
- At-the-Market Subscription Agreement
Later from Cynata Therapeutics
- Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
- Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial
- Cynata Completes $1.2m At-The-Market Raise
- December 2025 Quarterly Activity Report and Appendix 4C
- Appendix 4D & Half-Year Financial Statements
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics